These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38138247)

  • 1. Afatinib-Induced Tumor Lysis Syndrome in Pulmonary Adenocarcinoma: A Case Report and Literature Review.
    Hong G
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hyponatremia in a 58-year-old female patient with EGFR-positive lung adenocarcinoma].
    Koch M; Utpatel K; Schulz C
    Internist (Berl); 2018 Apr; 59(4):384-387. PubMed ID: 28980030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib.
    Ikeuchi T; Tokuyasu H; Ishikawa S
    Intern Med; 2019; 58(1):101-104. PubMed ID: 30606938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report.
    Cai Y; Wang X; Guo Y; Sun C; Xu Y; Qiu S; Ma K
    Medicine (Baltimore); 2019 Jan; 98(1):e13890. PubMed ID: 30608413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of afatinib and radiotherapy on a patient with lung adenocarcinoma with a rare EGFR extracellular domain M277E mutation and high PD-L1 expression.
    Lv D; Wang R; Wang X; Feng H
    J Cancer Res Ther; 2022 Apr; 18(2):587-589. PubMed ID: 35645132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report.
    Fang YF; Liu PC
    Thorac Cancer; 2021 Dec; 12(24):3429-3432. PubMed ID: 34729927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.
    Li SH; Hsieh MH; Fang YF
    Medicine (Baltimore); 2015 Oct; 94(41):e1739. PubMed ID: 26469914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature.
    Shi Y; Wang M
    Thorac Cancer; 2018 Dec; 9(12):1788-1794. PubMed ID: 30379401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
    Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.
    Liang SK; Ko JC; Yang JC; Shih JY
    Lung Cancer; 2019 Jul; 133():103-109. PubMed ID: 31200815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
    Li SH; Liu CY; Hsu PC; Fang YF; Wang CC; Kao KC; Tseng LC; Yang CT
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):81-89. PubMed ID: 29172778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer.
    Oyama B; Morikawa K; Sakaguchi T; Tsunoda A; Kida H; Inoue T; Mineshita M
    Intern Med; 2021; 60(3):441-444. PubMed ID: 33518612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
    Urbán L; Dóczi R; Vodicska B; Tihanyi D; Horváth M; Kormos D; Takács I; Pápai-Székely Z; Póka-Farkas Z; Várkondi E; Schwáb R; Hegedüs C; Vályi-Nagy I; Peták I
    Clin Lung Cancer; 2021 Jan; 22(1):e112-e115. PubMed ID: 33082101
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report.
    Iida Y; Kumasawa F; Shimizu T; Shintani Y; Takahashi N; Gon Y
    Thorac Cancer; 2020 Feb; 11(2):447-450. PubMed ID: 31779047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib Achieved Remarkable Disease Control in a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Exon 18-25 Kinase Domain Duplication.
    Wang XF; Zhao QT; Chen C
    Am J Ther; 2020; 27(5):e535-e537. PubMed ID: 31567148
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term survival in a patient with advanced lung adenocarcinoma harboring synchronous EGFR exon 18 G719A and BRAF V600E mutations and treated with afatinib: a case report.
    Huang Q; Chen C; Hu S; Wu H; Yu D; Zhu X; Xue C; Wu Y; Tang J; Xie R; Ran F
    Anticancer Drugs; 2022 Jan; 33(1):e730-e733. PubMed ID: 34387589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
    Zeng L; Xia C; Zhang Y; Yang N
    J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
    [No Abstract]   [Full Text] [Related]  

  • 18. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
    Hsu PC; Lee SH; Chiu LC; Lee CS; Wu CE; Kuo SC; Ju JS; Huang AC; Li SH; Ko HW; Yang CT; Wang CC
    Target Oncol; 2023 Mar; 18(2):195-207. PubMed ID: 36805452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib.
    Jia Y; Ali SM; Saad S; Chan CA; Miller VA; Halmos B
    Cancer Biol Ther; 2014 Aug; 15(8):970-4. PubMed ID: 24835218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.
    Zeng L; Zhang Y; Yang N
    J Thorac Oncol; 2018 Jun; 13(6):e93-e95. PubMed ID: 29793651
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.